Cullinan Therapeutics (CGEM) Competitors

$14.87 -0.86 (-5.47%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$15.26 +0.39 (+2.62%)

As of 07:25 AM Eastern

CGEM vs. VKTX, TLX, OGN, TWST, and TNGX

Should you buy Cullinan Therapeutics stock or one of its competitors? MarketBeat compares Cullinan Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cullinan Therapeutics include Viking Therapeutics (VKTX), Telix Pharmaceuticals (TLX), Organon & Co. (OGN), Twist Bioscience (TWST), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry.

How does Cullinan Therapeutics compare to Viking Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Cullinan Therapeutics' return on equity of -51.45% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Viking Therapeutics	N/A	-71.31%	-65.35%

Cullinan Therapeutics presently has a consensus price target of $30.75, suggesting a potential upside of 106.79%. Viking Therapeutics has a consensus price target of $95.50, suggesting a potential upside of 232.87%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.85

In the previous week, Cullinan Therapeutics had 2 more articles in the media than Viking Therapeutics. MarketBeat recorded 7 mentions for Cullinan Therapeutics and 5 mentions for Viking Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.28 beat Viking Therapeutics' score of 0.11 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Cullinan Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Summary

Cullinan Therapeutics beats Viking Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Telix Pharmaceuticals?

Cullinan Therapeutics (NASDAQ:CGEM) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Telix Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Telix Pharmaceuticals	$803.79M	4.34	-$7.12M	N/A	N/A

Telix Pharmaceuticals' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Telix Pharmaceuticals	N/A	N/A	N/A

In the previous week, Cullinan Therapeutics had 3 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 7 mentions for Cullinan Therapeutics and 4 mentions for Telix Pharmaceuticals. Cullinan Therapeutics' average media sentiment score of 1.28 beat Telix Pharmaceuticals' score of 0.62 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

86.3% of Cullinan Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cullinan Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

Cullinan Therapeutics presently has a consensus target price of $30.75, indicating a potential upside of 106.79%. Telix Pharmaceuticals has a consensus target price of $21.13, indicating a potential upside of 105.50%. Given Cullinan Therapeutics' higher possible upside, research analysts clearly believe Cullinan Therapeutics is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Telix Pharmaceuticals beats Cullinan Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Organon & Co. has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.42
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Organon & Co. has a net margin of 3.99% compared to Cullinan Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Organon & Co. presently has a consensus target price of $11.40, indicating a potential downside of 15.02%. Cullinan Therapeutics has a consensus target price of $30.75, indicating a potential upside of 106.79%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Organon & Co. has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the broader market.

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for Cullinan Therapeutics and 6 mentions for Organon & Co.. Cullinan Therapeutics' average media sentiment score of 1.28 beat Organon & Co.'s score of 0.91 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Organon & Co. beats Cullinan Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Twist Bioscience presently has a consensus target price of $56.57, indicating a potential upside of 13.62%. Cullinan Therapeutics has a consensus target price of $30.75, indicating a potential upside of 106.79%. Given Cullinan Therapeutics' higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Twist Bioscience. MarketBeat recorded 7 mentions for Cullinan Therapeutics and 6 mentions for Twist Bioscience. Cullinan Therapeutics' average media sentiment score of 1.28 beat Twist Bioscience's score of 0.64 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Twist Bioscience has higher revenue and earnings than Cullinan Therapeutics. Twist Bioscience is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	8.23	-$77.67M	-$1.33	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Twist Bioscience has a beta of 2.22, meaning that its share price is 122% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the broader market.

Cullinan Therapeutics has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Twist Bioscience's return on equity of -26.73% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

86.3% of Cullinan Therapeutics shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Twist Bioscience and Cullinan Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cullinan Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -41.54% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Tango Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market.

In the previous week, Tango Therapeutics had 6 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 13 mentions for Tango Therapeutics and 7 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.28 beat Tango Therapeutics' score of 0.53 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics presently has a consensus target price of $32.27, indicating a potential upside of 56.44%. Cullinan Therapeutics has a consensus target price of $30.75, indicating a potential upside of 106.79%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cullinan Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Tango Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$56.99M	52.36	-$101.59M	-$0.83	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Summary

Tango Therapeutics beats Cullinan Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Cullinan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEM vs. The Competition

Export

Metric	Cullinan Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$966.73M	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.32%
P/E Ratio	-4.43	18.13	20.64	25.23
Price / Sales	N/A	289.87	554.85	79.36
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	2.15	6.57	9.66	6.63
Net Income	-$219.88M	$24.35M	$3.56B	$335.59M
7 Day Performance	-7.93%	-2.53%	-1.65%	-1.20%
1 Month Performance	-1.26%	-3.55%	-2.60%	-1.16%
1 Year Performance	92.87%	53.51%	30.07%	28.10%

Cullinan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEM Cullinan Therapeutics	3.1555 of 5 stars	$14.87 -5.5%	$30.75 +106.8%	+98.3%	$966.73M	N/A	N/A	30	Positive News High Trading Volume
VKTX Viking Therapeutics	3.831 of 5 stars	$31.09 -2.0%	$95.50 +207.2%	+0.9%	$3.61B	N/A	N/A	20	Positive News
TLX Telix Pharmaceuticals	4.5108 of 5 stars	$10.30 -4.9%	$21.13 +105.2%	-38.4%	$3.50B	$803.79M	N/A	1,184	Positive News
OGN Organon & Co.	3.0719 of 5 stars	$13.31 -0.2%	$11.40 -14.3%	+48.7%	$3.49B	$6.16B	14.31	10,000
TWST Twist Bioscience	2.2676 of 5 stars	$55.30 -1.6%	$56.57 +2.3%	+61.0%	$3.48B	$376.57M	N/A	990	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEM) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. VKTX, TLX, OGN, TWST, and TNGX

How does Cullinan Therapeutics compare to Viking Therapeutics?

Summary

How does Cullinan Therapeutics compare to Telix Pharmaceuticals?

Summary

How does Cullinan Therapeutics compare to Organon & Co.?

Summary

How does Cullinan Therapeutics compare to Twist Bioscience?

Summary

How does Cullinan Therapeutics compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. VKTX, TLX, OGN, TWST, and TNGX

How does Cullinan Therapeutics compare to Viking Therapeutics?

Is CGEM or VKTX more profitable?

Do analysts rate CGEM or VKTX?

Does the media refer more to CGEM or VKTX?

Do institutionals and insiders have more ownership in CGEM or VKTX?

Which has higher valuation & earnings, CGEM or VKTX?

Which has more risk and volatility, CGEM or VKTX?

Summary

How does Cullinan Therapeutics compare to Telix Pharmaceuticals?

Which has stronger valuation and earnings, CGEM or TLX?

Is CGEM or TLX more profitable?

Does the media prefer CGEM or TLX?

Do institutionals & insiders believe in CGEM or TLX?

Which has more risk and volatility, CGEM or TLX?

Do analysts prefer CGEM or TLX?

Summary

How does Cullinan Therapeutics compare to Organon & Co.?

Which has better valuation and earnings, OGN or CGEM?

Do institutionals and insiders believe in OGN or CGEM?

Is OGN or CGEM more profitable?

Do analysts prefer OGN or CGEM?

Which has more volatility and risk, OGN or CGEM?

Does the media favor OGN or CGEM?

Summary

How does Cullinan Therapeutics compare to Twist Bioscience?

Do analysts recommend TWST or CGEM?

Does the media prefer TWST or CGEM?

Which has better earnings and valuation, TWST or CGEM?

Which has more volatility and risk, TWST or CGEM?

Is TWST or CGEM more profitable?

Do institutionals & insiders believe in TWST or CGEM?

Summary

How does Cullinan Therapeutics compare to Tango Therapeutics?

Do insiders and institutionals hold more shares of TNGX or CGEM?

Is TNGX or CGEM more profitable?

Which has more risk & volatility, TNGX or CGEM?

Does the media prefer TNGX or CGEM?

Do analysts rate TNGX or CGEM?

Which has higher earnings and valuation, TNGX or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools